Table 5

 Multivariate Cox proportional hazards model for Ki-67 index and treatment interaction for ER positive tumours*

VariableRFSBCS
RR95% CIp ValueRR95% CIp Value
*Adjusted for age (continuous), tumour size (T1 v T2), and nodal status (N0 v N+).
BCS, breast cancer survival; CI, confidence interval; IDC, invasive ductal carcinomas; ILC, invasive lobular carcinoma; MI, mitotic index; NHG, Nottingham histological grade; RFS, recurrence free survival; RR, relative risk.
Ki-67Intermediate v low + high0.850.50 to 1.460.560.810.51 to 1.690.93
TreatmentTamoxifen v control0.460.29 to 0.740.0010.610.36 to 1.020.06
Interaction variableTamoxifen × Ki-672.631.19 to 5.820.022.381.01 to 5.630.05
MI2 v 1+31.220.80 to 1.880.351.040.64 to 1.690.88
TreatmentTamoxifen v control0.600.38 to 0.940.020.660.40 to 1.090.10
Interaction variableTamoxifen × MI1.180.59 to 2.360.641.590.74 to 3.390.23
NHG3 v 1+21.861.17 to 2.950.0082.431.46 to 4.060.001
TreatmentTamoxifen v control0.620.40 to 0.960.030.760.45 to 1.250.28
Interaction variableTamoxifen × NHG0.940.46 to 1.920.870.960.44 to 2.050.91
Histological typeILC v IDC0.700.32 to 1.550.380.880.37 to 2.090.78
TreatmentTamoxifen v control0.590.40 to 0.850.0050.750.50 to 1.130.17
Interaction variableTamoxifen × type1.390.44 to 4.390.581.170.33 to 4.090.81